Calcineurin Inhibitor Market
Description
Calcineurin Inhibitor Market, By Drug Type (Cyclosporine, Tacrolimus, Pimecrolimus, Voclosporin, Others), By Route of Administration (Oral, Topical, Intravenous), By Indication (Organ Transplant Rejection Prevention, Autoimmune Diseases (e.g., Psoriasis, Atopic Dermatitis), Ophthalmic Diseases (e.g., Dry Eye Syndrome, Uveitis), Other Dermatological Conditions), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies),By End-User (Hospitals, Specialty Clinics, Dermatology Centers, Transplant Centers), and By Geography (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa)- Size, Share, Outlook, and Opportunity Analysis, 2023 - 2030
A calcineurin inhibitor is an immunosuppressant drug used in organ transplantation and other autoimmune conditions such as lupus erythematosus (SLE). Calcineurin inhibitors inhibit the activity of calcineurin, a serine-threonine phosphatase that activates T-cells, a type of leukocyte essential for cell-mediated immunity. They are usually given together with other immunosuppressive drugs in a combination known as a cyclosporine-based regimen, although some patients are treated solely with these agents. They can be administered orally, intravenously, topically or by injection. The most common calcineurin inhibitors are cyclosporine, tacrolimus and sirolimus.
Market Dynamics:
Increasing cases of autoimmune diseases and organ transplantation is expected to drive the growth of the global calcineurin inhibitor market in the coming future. Increasing demand for the calcineurin inhibitors to prevent rejection of transplanted organs is the major driving factor.
However, side effects associated with calcineurin inhibitors such as skin irritation and gastrointestinal disturbances may hamper the market growth. Moreover, risks connected with overdosing of the orally administered drugs such as nephrotoxicity and hepatotoxicity are also expected to impede the market growth in the coming future.
Key features of the study:
This report provides in-depth analysis of the global calcineurin inhibitor market, and provides market size (US$ Billion) and compound annual growth rate (CAGR%) for the forecast period (2023–2030), considering 2022 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global calcineurin inhibitor market based on the following parameters – company highlights, products portfolio, key highlights, financial performance, and strategies
Key companies covered as a part of this study include Novartis AG, Astellas Pharma Inc., LEO Pharma A/S, Allergan, Inc., Pfizer Inc., Sanofi SA, GlaxoSmithKline plc., Johnson & Johnson Services, Inc., Merck & Co., Inc., Roche Holding AG, Bristol Myers Squibb Company, AbbVie Inc., Eli Lilly and Company, Takeda Pharmaceutical Company Limited, and Mylan N.V.
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
The global calcineurin inhibitor market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global calcineurin inhibitor market
Detailed Segmentation:
Global Calcineurin Inhibitor Market, By Drug Type:
Cyclosporine
Tacrolimus
Pimecrolimus
Voclosporin
Others
Global Calcineurin Inhibitor Market, By Route of Administration:
Oral
Topical
Intravenous
Global Calcineurin Inhibitor Market, By Indication:
Organ Transplant Rejection Prevention
Autoimmune Diseases (e.g., Psoriasis, Atopic Dermatitis)
Ophthalmic Diseases (e.g., Dry Eye Syndrome, Uveitis)
Other Dermatological Conditions
Global Calcineurin Inhibitor Market, By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Global Calcineurin Inhibitor Market, By End-User:
Hospitals
Specialty Clinics
Dermatology Centers
Transplant Centers
Global Calcineurin Inhibitor Market, By Region:
North America
Europe
Asia Pacific
Latin America
Middle East and Africa
Company Profiles:
Novartis AG
Astellas Pharma Inc.
LEO Pharma A/S
Allergan, Inc.
Pfizer Inc.
Sanofi SA
GlaxoSmithKline plc
Johnson & Johnson Services, Inc.
Merck & Co., Inc.
Roche Holding AG
Bristol Myers Squibb Company
AbbVie Inc.
Eli Lilly and Company
Takeda Pharmaceutical Company Limited
Mylan N.V.
Table of Contents
130 Pages
- 1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
- 2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Calcineurin Inhibitor, By Drug Type
- Market Calcineurin Inhibitor, By Route of Administration
- Market Calcineurin Inhibitor, By Indication
- Market Calcineurin Inhibitor, By Distribution Channel
- Market Calcineurin Inhibitor, By End User
- Coherent Opportunity Map (COM)
- 3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Drivers
- Increasing cases of autoimmune diseases and organ transplantation
- Increasing demand for the calcineurin inhibitors
- Restraints
- Side effects
- Risks connected with overdosing
- Opportunities
- Rising investment in research and development to develop advanced calcineurin inhibitors
- Impact Analysis
- Key Highlights
- Regulatory Scenario
- Product launch/Approvals
- PEST Analysis
- PORTER’s Analysis
- Merger and Acquisition Scenario
- 4. Global Calcineurin Inhibitor Market – Impact of Coronavirus (COVID-19) Pandemic
- COVID-19 Epidemiology
- Supply Side and Demand Side Analysis
- Economic Impact
- 5. Global Calcineurin Inhibitor Market , By Drug Type, 2018-2030, (US$ Bn)
- Introduction
- Market Share Analysis, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, 2023 – 2030
- Segment Trends
- Cyclosporine
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Bn)
- Tacrolimus
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Bn)
- Pimecrolimus
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Bn)
- Voclosporin
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Bn)
- Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Bn)
- 6. Global Calcineurin Inhibitor Market , By Route of Administration, 2018-2030, (US$ Bn)
- Introduction
- Market Share Analysis, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, 2018– 2030
- Segment Trends
- Oral
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Billion)
- Topical
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Billion)
- Intravenous
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Billion)
- 7. Global Calcineurin Inhibitor Market , By Indication, 2018-2030, (US$ Bn)
- Introduction
- Market Share Analysis, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, 2018– 2030
- Segment Trends
- Organ Transplant Rejection Prevention
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Billion)
- Autoimmune Diseases
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Billion)
- Ophthalmic Diseases
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Billion)
- Other Dermatological Conditions
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Billion)
- 8. Global Calcineurin Inhibitor Market , By Distribution Channel, 2018-2030, (US$ Bn)
- Introduction
- Market Share Analysis, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, 2018– 2030
- Segment Trends
- Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Billion)
- Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Billion)
- Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Billion)
- 9. Global Calcineurin Inhibitor Market , By End User, 2018-2030, (US$ Bn)
- Introduction
- Market Share Analysis, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, 2018– 2030
- Segment Trends
- Hospitals
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Billion)
- Specialty Clinics
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Billion)
- Dermatology Centers
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Billion)
- Transplant Centers
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Billion)
- 10. Global Calcineurin Inhibitor Market , By Region, 2018-2030, (US$ Bn)
- Introduction
- Market Share Analysis, By Country, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, For Country 2023–2030
- Country Trends
- North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2018-2030,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2018-2030,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Indication, 2018-2030,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018-2030,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2018-2030,(US$ Bn)
- Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2018-2030,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2018-2030,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Indication, 2018-2030,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018-2030,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2018-2030,(US$ Bn)
- Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2018-2030,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2018-2030,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Indication, 2018-2030,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018-2030,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2018-2030,(US$ Bn)
- Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2018-2030,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2018-2030,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Indication, 2018-2030,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018-2030,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2018-2030,(US$ Bn)
- Middle East & Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2018-2030,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2018-2030,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Indication, 2018-2030,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018-2030,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2018-2030,(US$ Bn)
- 11. Competitive Landscape
- Novartis AG
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Astellas Pharma Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- LEO Pharma A/S
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Allergan, Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Pfizer Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Sanofi SA
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- GlaxoSmithKline plc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Johnson & Johnson Services, Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Merck & Co., Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Roche Holding AG
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Analyst Views
- 12. Section
- Research Methodology
- About us
- *Browse 24 market data tables and 28 figures on "Global Calcineurin Inhibitor Market” - Global forecast to 2030
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
